Leukocyte immunoglobulin-like receptor
Jump to navigation
Jump to search
Leukocyte immunoglobulin-like receptors (LIR) or CD85 have extracellular immunoglobulin domains. LIR modulates a variety of immune cells. LIR interacts with class I MHC molecules[1]. (PDB entry 1p7q). .
See also: |
|
3D structures of leukocyte immunoglobulin-like receptor3D structures of leukocyte immunoglobulin-like receptor
Updated on 10-July-2024
ReferencesReferences
- ↑ Thomas R, Matthias T, Witte T. Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):159-62. doi:, 10.1007/s12016-009-8148-8. PMID:19548123 doi:http://dx.doi.org/10.1007/s12016-009-8148-8
- ↑ Zeller T, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, Kellner C. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Front Immunol. 2023 Sep 13;14:1240275. PMID:37781391 doi:10.3389/fimmu.2023.1240275
- ↑ Mai S, Hodges A, Chen HM, Zhang J, Wang YL, Liu Y, Nakatsu F, Wang X, Fang J, Xu Y, Davidov V, Kang K, Pingali SR, Ganguly S, Suzuki M, Konopleva M, Prinzing B, Zu Y, Gottschalk S, Lu Y, Chen SH, Pan PY. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 Dec 15;83(24):4047-4062. PMID:38098451 doi:10.1158/0008-5472.CAN-22-2483
- ↑ Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 Jul 5;218(7):e20201811. PMID:33974041 doi:10.1084/jem.20201811